IMTH (Innovative MedTech) Debt-to-Equity : -0.45 (As of Sep. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Innovative MedTech Debt-to-Equity?

Innovative MedTech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1.71 Mil. Innovative MedTech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.54 Mil. Innovative MedTech's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $-5.03 Mil. Innovative MedTech's debt to equity for the quarter that ended in Sep. 2024 was -0.45.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Innovative MedTech's Debt-to-Equity or its related term are showing as below:

IMTH' s Debt-to-Equity Range Over the Past 10 Years
Min: -40.58 Med: -1.51 Max: -0.25
Current: -0.45

During the past 13 years, the highest Debt-to-Equity Ratio of Innovative MedTech was -0.25. The lowest was -40.58. And the median was -1.51.

IMTH's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.22 vs IMTH: -0.45

Innovative MedTech Debt-to-Equity Historical Data

The historical data trend for Innovative MedTech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovative MedTech Debt-to-Equity Chart

Innovative MedTech Annual Data

Trend

Oct10

Oct11

Oct12

Oct13

Oct14

Jun20

Jun21

Jun22

Jun23

Jun24

Debt-to-Equity

Get a 7-Day Free Trial

-0.71

-40.58

-1.66

-1.67

-0.40

Innovative MedTech Quarterly Data
	Jul14	Oct14	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															-1.62	-1.40	-1.63	-0.40	-0.45

Competitive Comparison of Innovative MedTech's Debt-to-Equity

For the Medical Instruments & Supplies subindustry, Innovative MedTech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovative MedTech's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Innovative MedTech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Innovative MedTech's Debt-to-Equity falls into.

Innovative MedTech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Innovative MedTech's Debt to Equity Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.667	+	0.527)	/	-5.483
	=	-0.40

Innovative MedTech's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.714	+	0.537)	/	-5.026
	=	-0.45

Innovative MedTech (OTCPK:IMTH) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Innovative MedTech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Innovative MedTech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovative MedTech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Innovative MedTech Inc (OTCPK:IMTH) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

2310 York Street, Suite 200, Blue Island, IL, USA, 60406

Website

https://www.innovativemedtech.com

Innovative MedTech Inc is a provider of health and wellness services. It develops, manufactures, and sells a variety of medical devices and supplies, including blood collection and infusion products, surgical instruments, and wound care products. The company operates in two divisions: technology and devices and Adult Day Services.

Executives

Merle Griff	officer: Chief Executive Officer	2310 YORK ST, SUITE 200, BLUE ISLAND IL 60406
Eddie Dovner	10 percent owner	70 SE 4TH AVE, DELRAY BEACH FL 33483
Charles Everhardt	director, 10 percent owner, other: Chairman of the Board	2310 YORK ST, STE 200, BLUE ISLAND IL 60406
Arthur Friedman	10 percent owner	280 MADISON AVE #1007, NEW YORK NY 10016
Marcia Roberts	10 percent owner	280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Michael Jordan Friedman	director, 10 percent owner, officer: President & CEO	280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Illuminate, Inc.	10 percent owner	881 KENNEDY BLVD., JERSEY CITL NJ 07002
A William Bodine	director, officer: CFO	280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Dominick M Cingari	director, officer: COO	280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Jay Odintz	director	280 MADISON AVENUE, NEW YORK NY 10016
Vincent L Verdiramo	director, officer: President	3163 KENNEDY BLVD, JERSEY CITY NJ 07306